Brind.
  1. Oncolytics Biotech is developing pelareorep, an immunotherapy candidate, which is being evaluated for various tumor types, including gastrointestinal tumors.
  2. Oncolytics Biotech is developing pelareorep, an immunotherapy candidate, which is being evaluated for various tumor types, including gastrointestinal tumors.
  3. Oncolytics Biotech is developing pelareorep, an immunotherapy candidate, which is being evaluated for various tumor types, including gastrointestinal tumors.
  4. Oncolytics Biotech is developing pelareorep, an immunotherapy candidate, which is being evaluated for various tumor types, including gastrointestinal tumors.

Oncolytics Biotech is developing pelareorep, an immunotherapy candidate, which is being evaluated for various tumor types, including gastrointestinal tumors.

6 reports, 3 independent Updated Jul 31
Gone quiet Reached 2 outlets in its first 24 hours
Reports
6
Developments
6
Repetition
17%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

Oncolytics Biotech is developing pelareorep, an immunotherapy candidate, which is being evaluated for various tumor types, including gastrointestinal tumors.

How it developed

Newest first. Tap a step to see who reported it.
  1. Co-development agreement reached between Oncolytics Biotech and Merck KGaA for pelareorep.1 source
  2. Oncolytics Biotech is developing pelareorep, an immunotherapy candidate, which is being evaluated for various tumor types, including gastrointestinal tumors.Sub-event
  3. Oncolytics Biotech is confident that the safety data for its pelareorep immunotherapy will satisfy regulators.1 source
  4. Pelareorep showed encouraging survival signals in mPDAC, leading to FDA support for an accelerated study strategy.1 source
  5. pelareorep is a systemically delivered oncolytic virus developed by Oncolytics Biotech.1 source
  6. Company provided updates and specified that pelareorep is an intravenously delivered oncolytic virus immunotherapy.

Keep exploring

Part of

Oncolytics Biotech is developing pelareorep, an immunotherapy candidate, which is being evaluated for various tumor types, including gastrointestinal tumors. The whole story

Within Oncolytics Biotech is developing pelareorep, an immunotherapy candidate, which is being evaluated for various tumor types, including gastrointestinal tumors.

Coverage

Newest first; wire copies grouped
  • tickerreport.com
  • CNW GroupOncolytics Biotech® Provides Updated Clinical Safety Data for Pelareorep, Including Across Multiple Gastrointestinal Tumors Data continue to demonstrate a favorable safety profile for pelareorep acro
  • PR NewswireOncolytics Biotech® Reports Second Quarter Financial Results and Details Clinical Program Plans for Pelareorep Key opinion leader event and pancreatic cancer clinical data validate decision to engage
  • CNW GroupOncolytics Biotech® to Engage FDA for Potential Registration-Enabled Study in First-Line Pancreatic Cancer with Goal to Launch Trial Activities by Year-End Clear regulatory path and strong survival d
  • PR NewswireOncolytics Biotech® Presents Aggregated Translational Data Providing Evidence of Pelareorep's Effectiveness Across Multiple Tumor Types Integrated biomarker analyses confirm viral replication, interf
  • Unknown outlet